Transpire Bio, which launched in 2022 to develop inhaled therapeutics for both local and systemic delivery, has officially opened its new headquarters and research facility in Weston, FL, USA. Shortly after launching, the company announced deals with Recipharm for development of 4 inhaled formulations (TRB-1, TRB-2, TRB-3, and TRB-4) and with INTO for 3 additional inhaled formulations (TRB-5, TRB-6, and TRB-7).
According to Transpire, the company intends to hire for 50 positions at the Florida location over the next 2 years. Previously announced hires include William Schachtner as Chief Technical Operations Officer, Axel Perlwitz as Chief Regulatory Affairs Officer, and Abhishek Gupta as Chief Scientific Officer and interim Chief Corporate Development Officer.
Transpire CEO Xian-Ming Zeng commented, “Transpire Bio is motivated by the opportunity to make a lasting impact on patients’ lives when it comes to inhaled therapies. Our mission is to develop generic and innovative inhalation products to improve patient access to essential medicines and address unmet medical needs.”
Read the Transpire Bio press release.
